Surgical outcome after neoadjuvant chemotherapy and bevacizumab: Results from the GeparQuinto study (GBG 44)

Annals of Surgical Oncology

Volumn 21, Issue 8, 2014, Pages 2517-2524

  Gerber, Bernd ^a   Von Minckwitz, Gunter ^b,k   Eidtmann, Holger ^c   Rezai, Mahdi ^d   Fasching, Peter ^e   Tesch, Hans ^f   Eggemann, Holm ^g   Schrader, Iris ^h   Kittel, Kornelia ⁱ   Hanusch, Claus ^j   Solbach, Christine ^k   Jackisch, Christian ^l   Kunz, Georg ^m   Blohmer, Jens Uwe ⁿ   Huober, Jens ^o   Hauschild, Maik ^p   Nekljudova, Valentina ^b   Loibl, Sibylle ^b   Untch, Michael ^q  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b German Breast Group ^*  (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Breast Center   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f Bethanien Krankenhaus Frankfurt   (Germany)

^g OTTO VON GUERICKE UNIVERSITY   (Germany)

^h Gynaeco Oncological Practice   (Germany)

ⁱ Breast Center   (Germany)

^j Rotkreuzklinikum   (Germany)

^k GOETHE UNIVERSITY   (Germany)

^l Offenbach Hospital   (Germany)

^m ST JOHANNES HOSPITAL   (Germany)

ⁿ Sankt Gertrauden Hospital   (Germany)

^o HEINRICH HEINE UNIVERSITY   (Germany)

^p Department of Senology   (Germany)

^q HELIOS KLINIKUM BERLIN BUCH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; EVEROLIMUS; PACLITAXEL; MONOCLONAL ANTIBODY; TAXOID;

ABSCESS; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; FEMALE; FEVER; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED TRIAL; SEGMENTAL MASTECTOMY; SURGICAL INFECTION; TISSUE NECROSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND HEALING IMPAIRMENT; ADJUVANT THERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; TAXOIDS; YOUNG ADULT;

EID: 84905126111     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3606-9     Document Type: Article

References (30)

1. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005;102:3738-43. (Pubitemid 40354681)
2. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299-309.
3. Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthrcycline-taxane based chemotherapy in 678 triple negative primary breast cancers; results from the GEPARQUINTO study (GBG 44). Ann Oncol. 2013;24(12):2978-84. doi:10.1093/annonc/mdt361.
4. Makhoul I, Klimberg VS, Korourian S, et al. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. Am J Clin Oncol. 2013. doi:10.1097/COC.0b013e31828940c3.
5. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039-45.
6. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-83.
7. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-11. (Pubitemid 350296300)
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44. (Pubitemid 46733080)
9. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91:173-80. (Pubitemid 41254420)
10. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-705.
11. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-96.
12. Reck M, Barlesi F, Crinò L, et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol. 2012;23:1111-20.
13. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227-34.
14. Soria JC, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24:20-30.
15. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol. 2011;22:595-602.
16. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-77. (Pubitemid 46622044)
17. Kriegel I, Cottu PH, Fourchotte V, et al. Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy. Anticancer Drugs. 2011;22:1020-3.
18. Cottu PH, Fourchotte V, Vincent-Salomon A, Kriegel I, Fromantin I. Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy. J Wound Care. 2011;20:403-4, 406, 408.
19. Lecarpentier E, Ouaffi L, Mir O, et al. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. Invest New Drugs. 2011;29:1500-3.
20. Lazzati V, Zygon J, Lohsiriwat V, Veronesi P, Petit JY. Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab. Aesthetic Plast Surg. 2010;34:796-7.
21. Kube R, Meyer F, Bien N, et al. Surgical management of bevacizumab-associated peritonitis due to perforation. Zentralbl Chir. 2009;134:462-7.
22. Kim HR, Jung KH, Im SA, et al. Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). Ann Oncol. 2013;24:1485-90.
23. Li CY, Shan S, Huang Q, et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst. 2000;92:143-7. (Pubitemid 30089871)
24. Huober J, Fasching PA, Hanusch C, et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) +/- bevacizumab - results of the randomised GeparQuinto study (GBG 44). Eur J Cancer. 2013;49:2284-93.
25. Bear HD, Tang G, Rastogi P, et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Res. 2011. doi:10.1158/0008-5472.SABCS11-PD07-08.
26. Golshan M, Garber JE, Gelman R, et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol. 2011;18:733-7.
27. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62:707-9.
28. Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, Solomon SB. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117:1296-301.
29. Cortes J, Caralt M, Delaloge S, et al. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer. 2012;48:475-81.
30. NCI. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm. Accessed 5 Nov 2013.